Renaissance Technologies’s Apimeds Pharmaceuticals US APUS Stock Holding History

Renaissance Technologies’s Portfolio APUS Stock Details APUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-2,789	Closed	-$49.6K	–	3915
2025 Q3	$49.6K	Buy	+2,789	New	+$51.7K	﹤0.01%	3344

Other funds holding APUS

HTHT

Hemenway Trust Hemenway Trust Salem, New Hampshire $1.43B AUM 37.14% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Renaissance Technologies's APUS Position: Q4 2025 in Review

Renaissance Technologies sold out of Apimeds Pharmaceuticals US (APUS) in Q4 2025, closing a stake of 2,789 shares — an estimated $49.6K sold.

Renaissance Technologies first reported a position in APUS in Q3 2025 and held it in 1 quarter. The position peaked at $49.6K in Q3 2025. 7 funds tracked by Wall St. Rank hold APUS as of Q4 2025.

Renaissance Technologies reported no remaining Apimeds Pharmaceuticals US position as of Q4 2025 after selling out during the quarter.
Renaissance Technologies sold 2,789 Apimeds Pharmaceuticals US shares in Q4 2025, an estimated $49.6K.
Renaissance Technologies first reported a position in Apimeds Pharmaceuticals US in Q3 2025 and held it in 1 quarter.
Renaissance Technologies's Apimeds Pharmaceuticals US position peaked at $49.6K in Q3 2025.
7 funds tracked by Wall St. Rank held Apimeds Pharmaceuticals US as of Q4 2025.

Based on Renaissance Technologies's 13F filing for Q4 2025, filed 12 Feb 2026.